Table 1.
Effect of CA feeding with or without co-treatment with PXR activators on liver function and total body weight
| ALT (U/l) | AST (U/l) | ALP (U/l) | Total bilirubin (μM) | Direct bilirubin (μM) | Change in total body weight (%) | |
|---|---|---|---|---|---|---|
| PXR+/+ | ||||||
| Control (4) | 23±4 | 45±6 | 42±6 | 10.4±1.28 | 4.27±0.44 | +2 |
| PCN (4) | 28±6 | 64±14 | 38±2 | 15.5±3.08 | 8.60±2.05 | NC |
| CA (6) | 1618±485a | 1350±356a | 202±32a | 39.3±7.52a | 33.8±10.4a | −23 |
| CA+PCN (5) | 358±77b | 380±108b | 62±12b | 12.0±1.20b | 7.52±0.68b | −12 |
| PXR−/− | ||||||
| Control (4) | 19±3 | 42±4 | 19±7 | 12.3±1.74 | 6.50±2.74 | +2 |
| PCN (4) | 13±5 | 38±12 | 11±6 | 15.8±4.10 | 11.2±4.27 | −10 |
| CA (4) | 95±8a | 91±3a | 31±7 | 10.7±1.54 | 6.87±1.03 | −15 |
| CA+PCN (4) | 85±6a | 80±13a | 23±5 | 15.3±1.37 | 7.58±0.68 | −18 |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine amino transferase; AST, aspartate aminotransferase; CA, cholic acid; PXR, pregnane X receptor; PCN, 5-pregnen-3β-ol-20-one-16α-carbonitrile; NC, no change.
PXR+/+ and PXR−/− mice were fed standard chow or a 1% CA-supplemented diet for 5 days with or without injection of the PXR activator PCN. Numbers in brackets indicate the number of mice in each treatment group. Blood samples were analysed for ALT, AST, ALP and bilirubin levels as indicators of liver function. Mice were weighed throughout the treatment period; the change in weight represents the difference in weight between the start and end of treatment. Results are presented as mean enzyme or bilirubin concentrations±s.e.m.
Significant from control P<0.05.
Significant from CA P<0.05.